(Q40921761)

English

Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.

scientific article published on July 1995

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 September 2017

1 reference

Europe PubMed Central

Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. (English)

1 reference

Europe PubMed Central

24 September 2017

hypercholesterolemia

0 references

author name string

I Hsu

1

1 reference

Europe PubMed Central

24 September 2017

S A Spinler

2

1 reference

Europe PubMed Central

24 September 2017

N E Johnson

3

1 reference

Europe PubMed Central

24 September 2017

language of work or name

0 references

publication date

1 July 1995

1 reference

Europe PubMed Central

24 September 2017

Annals of Pharmacotherapy

1 reference

Europe PubMed Central

24 September 2017

29

1 reference

Europe PubMed Central

24 September 2017

743-759

1 reference

Europe PubMed Central

24 September 2017

7-8

1 reference

Europe PubMed Central

24 September 2017

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Cholesterol and mortality. 30 years of follow-up from the Framingham study.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Racial differences in high-density lipoprotein cholesterol and coronary heart disease incidence in the usual-care group of the Multiple Risk Factor Intervention Trial.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

The value of lowering cholesterol after myocardial infarction.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Clinical implications of the biopharmaceutical properties of fluvastatin.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Inhibitors of hydroxymethylglutaryl coenzyme A reductase for treating hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Simvastatin in severe hypercholesterolaemia: a placebo controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Treatment of primary hypercholesterolaemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Simvastatin Pravastatin European Study Group.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Long-term safety and efficacy profile of simvastatin.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Updated clinical safety experience with fluvastatin.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Lovastatin-induced acute rhabdomyolysis.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Effects of lovastatin and pravastatin on sleep efficiency and sleep stages.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Lovastatin-associated sleep and mood disturbances.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP).

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Fluvastatin Long-Term Extension Trial (FLUENT): summary of efficacy and safety.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Long-term treatment of hypercholesterolemia with fluvastatin: a 52-week multicenter safety and efficacy study. French-Dutch Fluvastatin Study Group.

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1177%2F106002809502907-818

21 January 2018

Identifiers

10.1177/106002809502907-818

1 reference

Europe PubMed Central

24 September 2017

1 reference

Europe PubMed Central

24 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40921761&oldid=1219515439"